Literature DB >> 21616678

Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Sung Hee Choi1, Henry N Ginsberg.   

Abstract

Insulin resistance (IR) affects not only the regulation of carbohydrate metabolism but all aspects of lipid and lipoprotein metabolism. IR is associated with increased secretion of VLDL and increased plasma triglycerides, as well as with hepatic steatosis, despite the increased VLDL secretion. Here we link IR with increased VLDL secretion and hepatic steatosis at both the physiologic and molecular levels. Increased VLDL secretion, together with the downstream effects on high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) size, is proatherogenic. Hepatic steatosis is a risk factor for steatohepatitis and cirrhosis. Understanding the complex inter-relationships between IR and these abnormalities of liver lipid homeostasis will provide insights relevant to new therapies for these increasing clinical problems.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616678      PMCID: PMC3163828          DOI: 10.1016/j.tem.2011.04.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  163 in total

1.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

Authors:  Songtao Yu; Kimihiko Matsusue; Papreddy Kashireddy; Wen-Qing Cao; Vaishalee Yeldandi; Anjana V Yeldandi; M Sambasiva Rao; Frank J Gonzalez; Janardan K Reddy
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

2.  Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice.

Authors:  Emil D Bartels; Morten Lauritsen; Lars B Nielsen
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

3.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism.

Authors:  Michihiro Matsumoto; Seongah Han; Tadahiro Kitamura; Domenico Accili
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

4.  Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance.

Authors:  Roger Gutiérrez-Juárez; Alessandro Pocai; Claudia Mulas; Hiraku Ono; Sanjay Bhanot; Brett P Monia; Luciano Rossetti
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

Review 5.  Hepatic uptake of chylomicron remnants.

Authors:  A D Cooper
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

6.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

Authors:  Kimihiko Matsusue; Martin Haluzik; Gilles Lambert; Sun-Hee Yim; Oksana Gavrilova; Jerrold M Ward; Bryan Brewer; Marc L Reitman; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.

Authors:  Susan E Schadinger; Nancy L R Bucher; Barbara M Schreiber; Stephen R Farmer
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-01-11       Impact factor: 4.310

8.  Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans.

Authors:  Hélène Duez; Benoît Lamarche; René Valéro; Mirjana Pavlic; Spencer Proctor; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Circulation       Date:  2008-04-28       Impact factor: 29.690

9.  Proteomic and lipid characterization of apolipoprotein B-free luminal lipid droplets from mouse liver microsomes: implications for very low density lipoprotein assembly.

Authors:  Huajin Wang; Dean Gilham; Richard Lehner
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

10.  Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c.

Authors:  Guosheng Liang; Jian Yang; Jay D Horton; Robert E Hammer; Joseph L Goldstein; Michael S Brown
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

View more
  126 in total

1.  Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose.

Authors:  Raffaella Crescenzo; Francesca Bianco; Italia Falcone; Paola Coppola; Giovanna Liverini; Susanna Iossa
Journal:  Eur J Nutr       Date:  2012-04-28       Impact factor: 5.614

Review 2.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

Review 3.  Unexplained reciprocal regulation of diabetes and lipoproteins.

Authors:  Sei Higuchi; M Concepción Izquierdo; Rebecca A Haeusler
Journal:  Curr Opin Lipidol       Date:  2018-06       Impact factor: 4.776

4.  Molecular changes in hepatic metabolism in ZDSD rats-A new polygenic rodent model of obesity, metabolic syndrome, and diabetes.

Authors:  Lu Han; Stefanie Bittner; Dachuan Dong; Yuan Cortez; Alex Bittner; Jackie Chan; Meenakshi Umar; Wen-Jun Shen; Richard G Peterson; Fredric B Kraemer; Salman Azhar
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-24       Impact factor: 5.187

5.  Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes.

Authors:  Lorraine E Levitt Katz; Fida Bacha; Samuel S Gidding; Ruth S Weinstock; Laure El Ghormli; Ingrid Libman; Kristen J Nadeau; Kristin Porter; Santica Marcovina
Journal:  J Pediatr       Date:  2018-02-02       Impact factor: 4.406

6.  Reticulon 3 regulates very low density lipoprotein secretion by controlling very low density lipoprotein transport vesicle biogenesis.

Authors:  Shaila Siddiqi; Olga Zhelyabovska; Shadab A Siddiqi
Journal:  Can J Physiol Pharmacol       Date:  2018-05-14       Impact factor: 2.273

Review 7.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

8.  AIBP protects against metabolic abnormalities and atherosclerosis.

Authors:  Dina A Schneider; Soo-Ho Choi; Colin Agatisa-Boyle; Laurence Zhu; Jungsu Kim; Jennifer Pattison; Dorothy D Sears; Philip L S M Gordts; Longhou Fang; Yury I Miller
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

9.  FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.

Authors:  Dae Hyun Kim; Ting Zhang; Sojin Lee; Virtu Calabuig-Navarro; Jun Yamauchi; Ann Piccirillo; Yong Fan; Radha Uppala; Eric Goetzman; H Henry Dong
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

10.  Expanded granulocyte/monocyte compartment in myeloid-specific triple FoxO knockout increases oxidative stress and accelerates atherosclerosis in mice.

Authors:  Kyoichiro Tsuchiya; Marit Westerterp; Andrew J Murphy; Vidya Subramanian; Anthony W Ferrante; Alan R Tall; Domenico Accili
Journal:  Circ Res       Date:  2013-02-18       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.